As pow­er shifts hands in Wash­ing­ton, a top an­a­lyst pre­dicts an un­avoid­able war over ris­ing drug prices

The drug in­dus­try has two pow­er­ful rea­sons for buck­ing Pres­i­dent Don­ald Trump’s cam­paign to cap and low­er drug prices. As Bern­stein’s Ron­ny Gal sees it, they have to keep drug prices mov­ing up­ward to meet Wall Street’s ex­pec­ta­tions on their num­bers.

Threat­en­ing to re­al­ly shove prices north is al­so a good bar­gain­ing chip for the price ne­go­ti­a­tions to come in Wash­ing­ton DC, he adds. And the in­dus­try may soon have a long­time al­ly among the De­moc­rats in a key po­si­tion to in­flu­ence any drug pric­ing leg­is­la­tion to come.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.